963
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo

, , , , , , , , & show all
Pages 1046-1052 | Received 19 Apr 2018, Accepted 10 May 2018, Published online: 29 May 2018

References

  • Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
  • Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012;7:606–618.
  • Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.
  • Xu Y, Meng H. Paclitaxel-loaded stealth liposomes: development, characterization, pharmacokinetics, and biodistribution. Artif Cell Nanomed Biotechnol. 2016;44:350–355.
  • Ganassin R, Merker C, Rodrigues MC, et al. Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. Artif Cell Nanomed Biotechnol. 2017;1–11. DOI: 10.1080/21691401.2017.1408020
  • Afsharzadeh M, Hashemi M, Mokhtarzadeh A, et al. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cell Nanomed Biotechnol. 2017;1–16. DOI: 10.1080/21691401.2017.1376675
  • Suchocki P, Misiewicz I, Skupinska K, et al. The activity of Selol in multidrug-resistant and sensitive human leukemia cells. Oncol Rep. 2007;18(4): 893–899.
  • Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827–834.
  • Muehlmann L, Ma B, Longo J, et al. Aluminum & phthalocyanine chloride associated to poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as a new third-generation photosensitizer for anticancer photodynamic therapy. Int J Nanomed. 2014;9:1199.
  • Longo JPF, Muehlmann LA, Miranda-Vilela AL, et al. Prevention of distant lung metastasis after photodynamic therapy application in a breast cancer tumor model. J Biomed Nanotechnol. 2016;12:689–699.
  • de Souza LR, Muehlmann LA, Dos Santos MSC, et al. PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells. J Nanobiotechnol. 2014;12:32.
  • de Souza LR, Muehlmann LA, Matos LC, et al. Antitumor activity and systemic effects of PVM/MA-shelled selol nanocapsules in lung adenocarcinoma-bearing mice. Nanotechnology. 2015;26:505101.
  • dos Santos Câmara AL, Nagel G, Tschiche HR, et al. Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. Nanomedicine. 2017;12:1751–1765.
  • O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–449.
  • Mitry MA, Edwards JG. Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasc. 2016;10:17–24.
  • Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
  • Yuan, F, Dellian, M, Fukumura, D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752–3756.
  • Krishna, R, McIntosh, N, Riggs, KW, et al. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res. 1999;5(10):2939–2947.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.